Endocannabinoid involvement in endometriosis

 “Endometriosis is a disease common in women that is defined by abnormal extrauteral growths of uterine endometrial tissue and associated with severe pain. Partly because how the abnormal growths become associated with pain is poorly understood, the pain is difficult to alleviate without resorting to hormones or surgery, which often produce intolerable side effects or fail to help. Recent studies in a rat model and women showed that sensory and sympathetic nerve fibers sprout branches to innervate the abnormal growths. This situation, together with knowledge that the endocannabinoid system is involved in uterine function and dysfunction and that exogenous cannabinoids were once used to alleviate endometriosis-associated pain, suggests that the endocannabinoid system is involved in both endometriosis and its associated pain. Here, using a rat model, we found that CB1 cannabinoid receptors are expressed on both the somata and fibers of both the sensory and sympathetic neurons that innervate endometriosis’s abnormal growths. We further found that CB1 receptor agonists decrease, whereas CB1 receptor antagonists increase, endometriosis-associated hyperalgesia. Together these findings suggest that the endocannabinoid system contributes to mechanisms underlying both the peripheral innervation of the abnormal growths and the pain associated with endometriosis, thereby providing a novel approach for the development of badly-needed new treatments.”

“These findings implicate involvement of the endocannabinoid system in reproductive function and dysfunction. The endocannabinoid system plays a key role in pain mechanisms, and, previously, cannabinoids were long used by women to alleviate dysmenorrhea.”

“Together the findings suggest that the endocannabinoid system is involved in endometriosis and its associated pain via CB1 receptors and innervation of the ectopic growths. Using the rat model, we performed a combination of immunohistochemical and pharmacological studies to test this hypothesis and assess the endocannabinoid system’s potential as a target for new therapies.”

 Summary and conclusions

“These studies in a rat model of endometriosis provide evidence that endocannabinoids might regulate the innervation of the disease’s abnormal growths and that exogenous cannabinoid agents can be effective in reducing endometriosis symptoms. The fact that CB1 receptor expression is greater in the cysts than healthy uterus from the same rats suggests that treatments to activate CB1 receptors (either directly by CB1 agonists or indirectly by increasing relevant endocannabinoid levels) could be developed with minimal effects on uterine function. Although the rat model parallels many aspects of endometriosis in women, there are of course significant differences. However, when considered together with the past history of successful use of cannabinoids for alleviation of gynecological pains, and insofar as findings in rats can model mechanisms of endometriosis-related signs and symptoms, the present results suggest that approaches targeted at the endocannbinoid system represent a promising new direction for developing badly-needed new treatments for pain suffered by women with endometriosis.”

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972363/

Marijuana Compound Effective In Treating Tourette’s Syndrome, Study Says

“Thursday, 15 May 2003

Hanover, Germany: A primary compound in marijuana, delta-9-tetrahydrocannabinol (THC), is effective in reducing “tics” in patients suffering from Tourette’s Syndrome (TS), according to clinical trail data published in a recent edition of the Journal of Clinical Psychiatry. Tourette’s Syndrome is a complex neuropsychiatric disorder characterized by motor tics (sudden spasms especially in the facial muscles, neck and shoulders) and one or more vocal tics.

Twenty-four patients participated in the double-blind placebo-controlled trial over a period of six weeks. Treatment with up to 10 mg of THC resulted in significant improvement of tic severity, authors wrote. No serious adverse effects to the treatment were reported.

In a separate article published in Neuropsychopharmacology, authors elaborated, “No detrimental effect was seen on learning curve, interference, recall and recognition of word lists, immediate visual memory span, and divided attention” from THC during or after the treatment.

The 24-patient study confirmed previous smaller patient trials that also found THC to be effective in the treatment of tics and behavioral problems in patients with Tourette’s Syndrome.”

http://norml.org/news/2003/05/15/marijuana-compound-effective-in-treating-tourette-s-syndrome-study-says

Marijuana Successfully Treats Tourette’s Syndrome, Study Shows

“Thursday, 11 March 1999

German researchers report that the consumption of the marijuana compound THC alleviates symptoms of Tourette’s Syndrome. The researchers published their findings in this month’s issue of the American Journal of Psychiatry.

“Earlier reports suggested beneficial effects in Tourette’s syndrome when smoking marijuana,” the German research team wrote. “We report a successful treatment of Tourette’s syndrome with delta-9-tetrahydocannabinol, the major psychoactive ingredient of marijuana.”

Tourette’s syndrome is a complex neuropsychiatric disorder that is characterized by sudden spasms, so called “tics,” that occur especially in the face, neck, and shoulders.

The researchers found that a 25-year-old patient treated with 10 mg of THC experienced marked improvement of both vocal and motor tics associated with behavioral disorders. “The improvement began 30 minutes after treatment and lasted for about seven hours,” the researchers reported. “No adverse effects occurred.”

Researchers stated, “This is the first report of a successful treatment of Tourette’s syndrome with delta-9-THC.” They said they are planning to confirm their preliminary results in an upcoming double-blind, placebo controlled, crossover study.

NORML board member Dr. Lester Grinspoon of Harvard Medical School called inhaled marijuana’s effects on patients suffering from Tourette’s “impressive,” and said that the drug holds tremendous potential as a course of treatment for the disease.

For more information, please contact either Allen St. Pierre of The NORML Foundation @ (202) 483-8751 or NORML board member Dr. Lester Grinspoon of Harvard Medical School @ (617) 277-3621.”

http://norml.org/news/1999/03/11/marijuana-successfully-treats-tourette-s-syndrome-study-shows

[The endogenous cannabinoid system. Therapeutic implications for neurologic and psychiatric disorders].

Abstract

“For about 5,000 years, cannabis has been used as a therapeutic agent. There has been growing interest in the medical use of cannabinoids. This is based on the discovery that cannabinoids act with specific receptors (CB1 and CB2). CB1 receptors are located in specific brain areas (e.g. cerebellum, basal ganglia, and hippocampus) and CB2 receptors on cells of the immune system. Endogenous ligands of the cannabinoid receptors were also discovered (e.g. anandamids). Many physiologic processes are modulated by the two subtypes of cannabinoid receptor: motor functions, memory, appetite, and pain. These innovative neurobiologic/pharmacologic findings could possibly lead to the use of synthetic and natural cannabinoids as therapeutic agents in various areas. Until now, cannabinoids were used as antiemetic agents in chemotherapy-induced emesis and in patients with HIV-wasting syndrome. Evidence suggests that cannabinoids may prove useful in some other diseases, e.g. movement disorders such as Gilles de la Tourette’s syndrome, multiple sclerosis, and pain. These new findings also explain the acute adverse effects following cannabis use.”

http://www.ncbi.nlm.nih.gov/pubmed/15776259

Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report.

Abstract

“OBJECTIVE:

To describe the clinical course of the Delta 9-tetrahydrocannabinol (Delta 9-THC) treatment of a boy with Gilles de la Tourette Syndrome (TS) and comorbid attention-deficit/hyperactivity disorder (ADHD) in relation to Delta 9-THC plasma levels and intracortical inhibition measured by transcranial magnetic stimulation.

METHODS:

The clinical course and pharmacological and neurophysiological measures are reported in a 15-year-old boy with treatment refractory TS plus ADHD leading to severe physical and psychosocial impairment.

RESULTS:

Administration of Delta 9-THC improved tics considerably without adverse effects, allowing parallel stimulant treatment of comorbid ADHD. Along with the Delta 9-THC treatment, intracortical inhibition was increased, reflected in the enhanced short-interval intracortical inhibition and the prolongation of the cortical silent period.

CONCLUSIONS:

Our observation suggests that Delta 9-THC might be a successful alternative in patients with severe TS refractory to classic treatment. Particularly in the case of stimulant-induced exacerbation of tics, Delta 9-THC might enable successful treatment of comorbid ADHD. The enhancement of intracortical inhibition might be mediated by modulating release of several neurotransmitters including dopamine and gamma-aminobutyric acid. Further studies are needed to substantiate our findings.”

http://www.ncbi.nlm.nih.gov/pubmed/20520294

Cannabinoids improve driving ability in a Tourette’s patient.

“Cannabinoids improve driving ability in a Tourette’s patient.”
“For many patients diagnosed with a neuropsychiatric disorder, the ability to drive a car plays a crucial part in their functional autonomy. Surprisingly, there were no data available in a PubMed search performed in March 2011 concerning Tourette’s Syndrome and driving ability. According to our knowledge, this is the first report on driving ability in a drug-free Tourette’s patient as well as after cannabinoid therapy.”

Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome.

Abstract

“High densities of cannabinoid receptors were found in the basal ganglia and hippocampus, indicating a putative functional role of cannabinoids in movement and behaviour. Anecdotal reports suggested beneficial effects of marijuana in Tourette’s syndrome (TS). We therefore interviewed 64 TS patients with regard to use of marijuana and its influence on TS symptomatology. Of 17 patients (27%) who reported prior use of marijuana, 14 subjects (82%) experienced a reduction or complete remission of motor and vocal tics and an amelioration of premonitory urges and obsessive-compulsive symptoms. Our results provide more evidence that marijuana improves tics and behavioural disorders in TS. It can be speculated that cannabinoids might act through specific receptors, and that the cannabinoid system might play a major role in TS pathology.”

http://www.ncbi.nlm.nih.gov/pubmed/9879795

Cannabinoids reduce symptoms of Tourette’s syndrome.

Abstract

“Currently, the treatment of Tourette’s syndrome (TS) is unsatisfactory. Therefore, there is expanding interest in new therapeutical strategies. Anecdotal reports suggested that the use of cannabis might improve not only tics, but also behavioural problems in patients with TS. A single-dose, cross-over study in 12 patients, as well as a 6-week, randomised trial in 24 patients, demonstrated that Delta9-tetrahydrocannabinol (THC), the most psychoactive ingredient of cannabis, reduces tics in TS patients. No serious adverse effects occurred and no impairment on neuropsychological performance was observed. If well-established drugs either fail to improve tics or cause significant adverse effects, in adult patients, therapy with Delta9-THC should be tried. At present, it remains unclear whether herbal cannabis, different natural or synthetic cannabinoid CB1-receptor agonists or agents that interfere with the inactivation of endocannabinoids, may have the best adverse effect profile in TS.”

http://www.ncbi.nlm.nih.gov/pubmed/14521482

Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.

“Preliminary studies suggested that delta-9-tetrahydrocannabinol (THC), the major psychoactive ingredient of Cannabis sativa L., might be effective in the treatment of Tourette syndrome (TS).

This study was performed to investigate for the first time under controlled conditions, over a longer-term treatment period, whether THC is effective and safe in reducing tics in TS.

CONCLUSION:

Our results provide more evidence that THC is effective and safe in the treatment of tics. It, therefore, can be hypothesized that the central cannabinoid receptor system might play a role in TS pathology.”

https://www.ncbi.nlm.nih.gov/pubmed/12716250

“Our results provide more evidence that THC is effective and safe in the treatment of tics.” http://www.psychiatrist.com/jcp/article/Pages/2003/v64n04/v64n0417.aspx

Treatment of Tourette Syndrome with Delta-9-Tetrahydrocannabinol (9-THC): No Influence on Neuropsychological Performance

“Previous studies provide evidence that marijuana (Cannabis sativa) and delta-9-tetrahydrocannabinol (Delta(9)-THC), the major psychoactive ingredient of marijuana, respectively, are effective in the treatment of tics and behavioral problems in Tourette syndrome (TS). It, therefore, has been speculated that the central cannabinoid receptor system might be involved in TS pathology. However, in healthy marijuana users there is an ongoing debate as to whether the use of cannabis causes acute and/or long-term cognitive deficits. In this randomized double-blind placebo-controlled study, we investigated the effect of a treatment with up to 10 mg Delta(9)-THC over a 6-week period on neuropsychological performance in 24 patients suffering from TS. During medication and immediately as well as 5-6 weeks after withdrawal of Delta(9)-THC treatment, no detrimental effect was seen on learning curve, interference, recall and recognition of word lists, immediate visual memory span, and divided attention. Measuring immediate verbal memory span, we even found a trend towards a significant improvement during and after treatment. Results from this study corroborate previous data suggesting that in patients suffering from TS, treatment with Delta(9)-THC causes neither acute nor long-term cognitive deficits. Larger and longer-duration controlled studies are recommended to provide more information on the adverse effect profile of THC in patients suffering from TS.”

“Anecdotal reports and two controlled studies provide evidence that marijuana (Cannabis sativa) and delta-9-tetrahydrocannabinol (THC), the major psychoactive ingredient of marijuana, respectively, are effective in the treatment of tics and behavioral problems in TS.”

“In conclusion, our data are in agreement with anecdotal reports and a pilot study suggesting that -THC treatment in patients suffering from TS has no detrimental effect on neuropsychological performance. We hypothesize that the effects of -THC on cognition in TS patients might be different from those in healthy marijuana users because of the pathology of the disease. Since there is evidence that tics can be improved by THC, an involvement of the central CB1 receptor system in TS pathology has been suggested. However, larger and longer-duration controlled studies are recommended to provide more information on the adverse effect profile of THC in patients suffering from TS.”

http://www.nature.com/npp/journal/v28/n2/full/1300047a.html